News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
170,977 Results
Type
Article (7089)
Company Profile (110)
Press Release (163778)
Multimedia
Podcasts (47)
Webinars (7)
Section
Business (53986)
Career Advice (392)
Deals (9789)
Drug Delivery (30)
Drug Development (32037)
Employer Resources (71)
FDA (2757)
Job Trends (4157)
News (96819)
Policy (6795)
Tag
2024 BioCapital Digital (3)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (4)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Biotech Bay Standard (6)
2024 Biotech Beach Digital (2)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (1)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (3)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (269)
Accelerated approval (1)
Adcomms (2)
Allergies (28)
Alliances (12332)
ALS (34)
Alzheimer's disease (396)
Antibody-drug conjugate (ADC) (56)
Approvals (2780)
Artificial intelligence (72)
Autoimmune disease (8)
Automation (1)
Bankruptcy (64)
Best Places to Work (3228)
BIOSECURE Act (14)
Biosimilars (42)
Biotechnology (72)
Bladder cancer (18)
Brain cancer (13)
Breast cancer (59)
Cancer (647)
Cardiovascular disease (41)
Career advice (336)
Career pathing (21)
CAR-T (56)
Cell therapy (135)
Cervical cancer (4)
Clinical research (27131)
Collaboration (269)
Compensation (274)
Complete response letters (8)
COVID-19 (663)
CRISPR (8)
C-suite (105)
Cystic fibrosis (25)
Data (753)
Decentralized trials (1)
Denatured (12)
Depression (15)
Diabetes (62)
Diagnostics (619)
Digital health (2)
Diversity (6)
Diversity, equity & inclusion (20)
Drug discovery (30)
Drug pricing (22)
Drug shortages (3)
Duchenne muscular dystrophy (21)
Earnings (23129)
Editorial (26)
Employer branding (10)
Employer resources (62)
Events (33973)
Executive appointments (305)
FDA (3106)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (206)
Gene editing (19)
Generative AI (9)
Gene therapy (70)
GLP-1 (251)
Government (745)
Grass and pollen (1)
Guidances (15)
Healthcare (2356)
Huntington's disease (9)
IgA nephropathy (7)
Immunology and inflammation (33)
Indications (12)
Infectious disease (694)
Inflammatory bowel disease (47)
Inflation Reduction Act (6)
Influenza (7)
Intellectual property (36)
Interviews (75)
IPO (5775)
IRA (14)
Job creations (1025)
Job search strategy (278)
Kidney cancer (5)
Labor market (26)
Layoffs (133)
Leadership (14)
Legal (917)
Liver cancer (23)
Lung cancer (104)
Lymphoma (47)
Machine learning (2)
Management (24)
Manufacturing (113)
MASH (40)
Medical device (467)
Medtech (468)
Mergers & acquisitions (4260)
Metabolic disorders (227)
Multiple sclerosis (30)
NASH (8)
Neurodegenerative disease (28)
Neuropsychiatric disorders (7)
Neuroscience (572)
NextGen: Class of 2025 (1002)
Non-profit (248)
Northern California (1068)
Now hiring (28)
Obesity (121)
Opinion (79)
Ovarian cancer (30)
Pain (25)
Pancreatic cancer (20)
Parkinson's disease (41)
Partnered (3)
Patents (69)
Patient recruitment (44)
Peanut (15)
People (17325)
Pharmaceutical (38)
Pharmacy benefit managers (1)
Phase I (8208)
Phase II (12504)
Phase III (9113)
Pipeline (461)
Policy (67)
Postmarket research (511)
Preclinical (3080)
Press Release (19)
Prostate cancer (22)
Psychedelics (12)
Radiopharmaceuticals (112)
Rare diseases (102)
Real estate (1203)
Recruiting (29)
Regulatory (5743)
Reports (22)
Research institute (289)
Resumes & cover letters (43)
RNA editing (1)
RSV (11)
Schizophrenia (39)
Series A (35)
Series B (24)
Service/supplier (4)
Sickle cell disease (8)
Southern California (842)
Special edition (16)
Spinal muscular atrophy (43)
Sponsored (5)
Startups (963)
State (1)
Stomach cancer (1)
Supply chain (16)
Tariffs (15)
The Weekly (34)
United States (7932)
Vaccines (163)
Venture capitalists (16)
Weight loss (58)
Women's health (7)
Worklife (12)
Date
Today (36)
Last 7 days (152)
Last 30 days (934)
Last 365 days (11833)
2025 (3296)
2024 (12599)
2023 (14384)
2022 (16290)
2021 (17907)
2020 (15274)
2019 (10056)
2018 (7218)
2017 (8972)
2016 (7369)
2015 (9363)
2014 (7128)
2013 (5128)
2012 (4952)
2011 (4878)
2010 (4829)
Location
Africa (171)
Alabama (18)
Arizona (19)
Arkansas (2)
Asia (13586)
Australia (1497)
California (2215)
Canada (515)
China (311)
Colorado (80)
Connecticut (90)
Delaware (72)
Europe (24613)
Florida (278)
Georgia (71)
Idaho (3)
Illinois (104)
India (8)
Indiana (82)
Iowa (5)
Japan (59)
Kansas (52)
Kentucky (7)
Maine (3)
Maryland (231)
Massachusetts (1772)
Michigan (35)
Minnesota (76)
Missouri (17)
Nebraska (6)
Nevada (4)
New Hampshire (4)
New Jersey (803)
New Mexico (7)
New York (754)
North Carolina (356)
Northern California (1068)
Ohio (67)
Oklahoma (4)
Oregon (12)
Pennsylvania (407)
Puerto Rico (7)
Rhode Island (7)
South America (220)
Southern California (842)
Tennessee (9)
Texas (216)
Utah (51)
Virginia (42)
Washington D.C. (13)
Washington State (150)
Wisconsin (9)
170,977 Results for "cue biopharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Cue Biopharma to Host Business Update Call and Webcast
April 14, 2025
·
1 min read
Press Releases
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
April 15, 2025
·
6 min read
Collaboration
Boehringer Ingelheim Boosts I&I Portfolio With $357M in Biobucks for Cue
At the heart of the licensing deal is CUE-501, a bispecific molecule that can selectively deplete B cells to address autoimmune and inflammatory conditions.
April 15, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
April 14, 2025
·
8 min read
Press Releases
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
April 1, 2025
·
8 min read
Genetown
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
Cue Biopharma today announced updated data from its ongoing Phase 1 trial evaluating its lead oncology asset from the CUE-100 series of biologics, CUE-101.
June 4, 2024
·
9 min read
Press Releases
Cue Biopharma Announces Strategic Organizational Transition
November 14, 2024
·
7 min read
Genetown
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
Cue Biopharma, Inc. today announced that it will participate in two investor conferences this June, the Jefferies Global Healthcare Conference, to be held in New York, NY, June 4-6 and the Oppenheimer Novel Targets and Immunology Summit, to be held in New York, NY on June 24.
June 3, 2024
·
2 min read
Genetown
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
Cue Biopharma, Inc. announced that it will take part in a fireside chat at The Citizens JMP Life Sciences Conference being held in New York, May 13-14, 2024.
May 7, 2024
·
1 min read
Genetown
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
Cue Biopharma, Inc. announced today that the company’s lead clinical asset, CUE-101, will be featured in a presentation at the 2024 Multi-disciplinary Head and Neck Cancers Symposium given by Alexander Dimitrios Colevas, M.D., a principal investigator at Stanford University participating in the CUE-101 clinical trial.
February 29, 2024
·
3 min read
1 of 17,098
Next
